Clinical characteristics and functional outcome of pediatric ocular trauma in a third level reference hospital in Guadalajara, Mexico - Zepeda-Romero LC, Saucedo-Rodr íguez LR, Becerra-Cota M, Gutiérrez-Padilla JA, Yanowsky-Reyes G, Pérez-Rulfo-Ibarra D, Díaz-Borrayo N, Cabrera-Díaz NN, Barrera-de-León JC.
BACKGROUND: Ocular trauma is one of the leading causes of decreased visual acuity and monocular blindness in the pediatric population. Since its occurrence is potentially preventable, it is essential to understand its demographic characteristics and risk f... (Source: SafetyLit)
Source: SafetyLit - January 31, 2022 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Investor Update - January 31, 2022 Category: Pharmaceuticals Source Type: news
FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Media News - January 31, 2022 Category: Pharmaceuticals Source Type: news
Does expertise reduce rates of inattentional blindness? A meta-analysis - Ekelund M, Fernsund H, Karlsson S, Mac Giolla E.
Inattentional blindness occurs when one fails to notice a fully visible stimulus because one's attention is on another task. Researchers have suggested that expertise at this other task should reduce rates of inattentional blindness. However, research on t... (Source: SafetyLit)
Source: SafetyLit - January 27, 2022 Category: International Medicine & Public Health Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news
Pediatric open globe injury in tertiary hospitals of Khobar and Dhahran - Al Majed FA, Al Shamlan FT, Alawazem MA, Alsadah HH, Al Beshri HS, Al Abdulwahhab MA.
This study aimed to review and discuss the epidemiology, causes, and clinical outcom... (Source: SafetyLit)
Source: SafetyLit - January 27, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
